EMYRIA LIMITED — Investor Presentation 2021

Jun 6, 2021

ASX Announcement

07/06/21

Emyria Investor Webinar

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed treatment development and clinical services company, is pleased to invite shareholders to an Investor Briefing to be held on 8 June at 11:45 am AEDT

Emyria’s Managing Director and CEO, Dr, Michael Winlo will present an overview of today’s release “Emyria Data Validated, Care Model Reduces Opioids” and provide the latest preliminary results of a collaboration between Emyria, IQVIA (NYSE:IQV) and NostraData.

Details of the event are as follows:

• Event: Emyria Investor Webinar

• Webinar Presenter: Emyria’s Managing Director, Dr, Michael Winlo

• Date and Time: Tuesday 8 June 2021, 11:45am AEDT

• Where : Zoom Webinar - details to be provided upon registration

To register your interest in the webinar please click through to the link below.

Registration Link:

- https://janemorganmanagement au.zoom.us/webinar/register/WN_qCzy0GPsT0ivAYi4RgjLVw

After registering your interest, you will receive a confirmation email with information about joining the webinar. Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to Lexi O’Halloran at: lexi@janemorganmanagement.com.au

Highlights:

• Analysis of large drug community dispensing data shows a significant reduction in opioid use following commencement of a personalised treatment program involving cannabinoid medicine at Emyria’s Emerald Clinics

• Opioid prescription dispensing data provided by IQVIA (NYSE: IQV) and NostraData validates the quality and utility of Emyria’s proprietary clinical data

• The data show that, on average opioid consumption reduces after commencing care at Emerald Clinics from a previous 12 month steady-state of opioid-use

• Opioid abuse continues to be a major health issue worldwide, with nearly 50,000 people dying per year in the USA alone from opioid-involved overdoses [1]

• Emyria will further and deeply analyse the data to assess potential for new registered treatments with the FDA for opioid-sparing[AV1] .

1

==> picture [137 x 40] intentionally omitted <==

• Emyria to present data to health insurers and payers for increased clinic and patient funding and expansion support for better health outcomes and potential health

• Emyria has engaged Professor David Preen , Chair of Public Health at UWA and Chief Investigator for the Centre of Research Excellence in Medicines Intelligence to continue independent research on Emyria Data [2]

• Emyria to continue investment in care model innovation and proprietary, software-powered clinical decision support tools backed by Emyria Data

This announcement has been approved and authorised by the Board of Emyria Limited.

For further information on Emyria :

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Emyria’s first drug development program, EMD-003 is targeting unmet needs in mental health. Specifically psychological distress and the symptoms of anxiety, depression and stress.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

2